327 related articles for article (PubMed ID: 35893290)
21. Neural stem cells at the crossroads: MMPs may tell the way.
Tonti GA; Mannello F; Cacci E; Biagioni S
Int J Dev Biol; 2009; 53(1):1-17. PubMed ID: 19123122
[TBL] [Abstract][Full Text] [Related]
22. Matrix Metalloproteinases During Axonal Regeneration, a Multifactorial Role from Start to Finish.
Andries L; Van Hove I; Moons L; De Groef L
Mol Neurobiol; 2017 Apr; 54(3):2114-2125. PubMed ID: 26924318
[TBL] [Abstract][Full Text] [Related]
23. Implication of matrix metalloproteinases in regulating neuronal disorder.
Mukherjee A; Swarnakar S
Mol Biol Rep; 2015 Jan; 42(1):1-11. PubMed ID: 25374425
[TBL] [Abstract][Full Text] [Related]
24. The potential use of MMP inhibitors to treat CNS diseases.
Yong VW
Expert Opin Investig Drugs; 1999 Mar; 8(3):255-68. PubMed ID: 15992076
[TBL] [Abstract][Full Text] [Related]
25. Tissue mRNA expression in rat of newly described matrix metalloproteinases.
Bernal F; Hartung HP; Kieseier BC
Biol Res; 2005; 38(2-3):267-71. PubMed ID: 16238105
[TBL] [Abstract][Full Text] [Related]
26. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases: their biological functions and clinical implications.
Hijova E
Bratisl Lek Listy; 2005; 106(3):127-32. PubMed ID: 16026148
[TBL] [Abstract][Full Text] [Related]
28. Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.
Zakiyanov O; Kalousová M; Zima T; Tesař V
Kidney Blood Press Res; 2019; 44(3):298-330. PubMed ID: 31185475
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions.
Maeda A; Sobel RA
J Neuropathol Exp Neurol; 1996 Mar; 55(3):300-9. PubMed ID: 8786388
[TBL] [Abstract][Full Text] [Related]
30. Elevated concentrations of serum matrix metalloproteinase-2 and -9 and their associations with circulating markers of cardiovascular diseases in chronic arsenic-exposed individuals.
Islam MS; Mohanto NC; Karim MR; Aktar S; Hoque MM; Rahman A; Jahan M; Khatun R; Aziz A; Salam KA; Saud ZA; Hossain M; Rahman A; Mandal A; Haque A; Miyataka H; Himeno S; Hossain K
Environ Health; 2015 Dec; 14():92. PubMed ID: 26637202
[TBL] [Abstract][Full Text] [Related]
31. Interplay between perivascular and perineuronal extracellular matrix remodelling in neurological and psychiatric diseases.
Ulbrich P; Khoshneviszadeh M; Jandke S; Schreiber S; Dityatev A
Eur J Neurosci; 2021 Jun; 53(12):3811-3830. PubMed ID: 32594588
[TBL] [Abstract][Full Text] [Related]
32. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
33. Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.
Diekmann U; Zarbock R; Hendig D; Szliska C; Kleesiek K; Götting C
J Mol Med (Berl); 2009 Oct; 87(10):965-70. PubMed ID: 19575173
[TBL] [Abstract][Full Text] [Related]
34. [Extracellular matrix -- from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases].
Hamacher S; Matern S; Roeb E
Dtsch Med Wochenschr; 2004 Sep; 129(38):1976-80. PubMed ID: 15375740
[TBL] [Abstract][Full Text] [Related]
35. Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
Narula S; Tandon C; Tandon S
Curr Med Chem; 2018; 25(15):1805-1816. PubMed ID: 29210632
[TBL] [Abstract][Full Text] [Related]
36. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
Olejarz W; Łacheta D; Kubiak-Tomaszewska G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486345
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).
Łukaszewicz-Zając M; Mroczko B; Słowik A
J Neural Transm (Vienna); 2014 Nov; 121(11):1387-97. PubMed ID: 25047909
[TBL] [Abstract][Full Text] [Related]
38. The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?
Koutroulis I; Zarros A; Theocharis S
Expert Opin Ther Targets; 2008 Dec; 12(12):1577-86. PubMed ID: 19007324
[TBL] [Abstract][Full Text] [Related]
39. IL-12-mediated transcriptional regulation of matrix metalloproteinases.
Roupakia E; Markopoulos GS; Kolettas E
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29555826
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
